Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease

• Main Authors: A. A. Tappakhov, T. E. Popova, T. G. Govorova, N. A. Shnaider, M. R. Sapronova
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2020-02-01
• Series: Nevrologiâ, Nejropsihiatriâ, Psihosomatika
• Subjects: parkinson's disease; levodopa; dopamine; drug-induced dyskinesias, personalized medicine
• Online Access: https://nnp.ima-press.net/nnp/article/view/1268

Levodopa remains the gold standard of treating Parkinson's disease (PD). However, the inevitable complication of levodopa therapy is druginduced dyskinesias, which significantly limits the therapeutic capabilities of this group of drugs and requires treatment adjustment. At the same time, patients with PD show not only a wide interindividual variability in the response to levodopa treatment, but also differences in the frequency and time to onset of drug-induced dyskinesias. Therefore, genetic predisposition can play an important role in the development of complications of levodopa therapy.The paper reviews modern literature on the impact of mutations in the genes, the products of which are involved in the exchange of levodopa and are capable of provoking or, conversely, levelling the development of drug-induced dyskinesias in order to determine the possibilities of expanding the personalized approach to treating patients with PD.